Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses (2022 - 2025)

Amylyx Pharmaceuticals (AMLX) has 4 years of Change in Accured Expenses data on record, last reported at -$1.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 95.42% year-over-year to -$1.2 million; the TTM value through Dec 2025 reached -$6.6 million, up 88.97%, while the annual FY2025 figure was -$6.6 million, 88.97% up from the prior year.
  • Change in Accured Expenses reached -$1.2 million in Q4 2025 per AMLX's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $20.8 million in Q4 2023 and bottomed at -$26.4 million in Q4 2024.
  • Average Change in Accured Expenses over 4 years is -$2.3 million, with a median of -$146000.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: crashed 8879.45% in 2024, then skyrocketed 143.08% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at $5.7 million in 2022, then surged by 267.58% to $20.8 million in 2023, then plummeted by 227.07% to -$26.4 million in 2024, then skyrocketed by 95.42% to -$1.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$1.2 million in Q4 2025, $1.1 million in Q3 2025, and $5.4 million in Q2 2025.